|
業務類別
|
Biotechnology |
|
業務概覽
|
Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor. |
| 公司地址
| 780 Brannan Street, San Francisco, CA, USA, 94103 |
| 電話號碼
| +1 415 651-3316 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.olema.com |
| 員工數量
| 131 |
| Dr. Sean P. Bohen, M.D.,PhD |
Director, President and Chief Executive Officer |
美元 699.92K |
13/08/2026 |
| Ms. Shawnte M. Mitchell, J.D. |
Chief Legal Officer and Corporate Secretary |
美元 391.88K |
29/04/2026 |
| Dr. David C. Myles, PhD |
Chief Scientific Officer |
-- |
29/04/2026 |
| Dr. Naseem Zojwalla, M.D. |
Chief Medical Officer |
-- |
29/04/2026 |
| Mr. Jason O'Byrne |
Chief Financial Officer |
-- |
13/08/2026 |
| Ms. Sasha Lu Austin |
Vice President, Finance and Controller |
-- |
16/03/2026 |
|
|
| Mr. Andrew S. Rappaport |
Independent Director |
29/04/2026 |
| Ms. Cynthia M. Butitta |
Independent Director |
29/04/2026 |
| Mr. Ian T. Clark |
Chairman of the Board |
29/04/2026 |
| Dr. Sandra J. Horning, M.D. |
Independent Director |
29/04/2026 |
| Mr. Scott Garland |
Independent Director |
29/04/2026 |
| Dr. Sean P. Bohen, M.D.,PhD |
Director, President and Chief Executive Officer |
13/08/2026 |
| Dr. Graham Walmsley, M.D.,PhD |
Independent Director |
29/04/2026 |
| Ms. Yi Larson |
Independent Director |
29/04/2026 |
| Dr. Cyrus L. Harmon, PhD |
Independent Director |
29/04/2026 |
| Dr. Prakash Raman, PhD |
Independent Director |
29/04/2026 |
|
|
|
|